Analysis of the final APEX Phase 1b clinical results obtained with KSI-101 (Kodiak Sciences Inc.) evaluated to treat macular edema secondary to inflammation (MESI) showed that at week 24 well over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results